Table 1. Baseline clinical and laboratory data of 182 patients with non-diabetic chronic kidney disease stratified by GFR stages according to K/DOQI guidelines.
| GFR (mL/min/1.73 m2) | ||||||
| ≥90 | 60–89 | 30–59 | <30 | |||
| Variable | all patients | (n = 59) | (n = 35) | (n = 51) | (n = 37) | p-value |
| Sex: males/females, n (%) | 122/60 | 41/18 | 24/11 | 35/16 | 22/15 | 0.75 |
| (67.0/33.0) | (69.5/30.5) | (68.6/31.4) | (68.6/31.4) | (59.5/40.5) | ||
| Age (years) | 45.8±12.8 | 40.5±13.4 | 45.8±12.3 | 45.9±11.7 | 54.2±9.0 | <0.001 |
| BMI (kg/m2) | 25.21±3.6 | 24.2±3.3 | 25.8±3.6 | 25.1±3.1 | 26.2±4.3 | 0.04 |
| Current smokers, n (%) | 36 (20) | 15 (25) | 8 (23) | 6 (12) | 7 (19) | 0.73 |
| Systolic blood pressure (mmHg) | 137±21 | 135±22 | 138±25 | 138±18 | 138±19 | 0.82 |
| Diastolic blood pressure (mmHg) | 86±13 | 83±13 | 86±13 | 86±13 | 88±14 | 0.40 |
| Serum albumin (g/dL) | 4.6±0.4 | 4.7±0.4 | 4.4±0.6 | 4.6±0.4 | 4.5±0.4 | 0.005 |
| Proteinuria (g/24 h/1.73 m2) | 0.90±0.90 | 0.56±0.65 | 1.10±1.11 | 1.01±0.95 | 1.10±0.81 | 0.001 |
| (0.18;0.55;1.26) | (0.12;.0.35;0.73) | (0.17;0.60;1.80) | (0.22;0.55;1.78) | (0.54;0.95;1.52) | ||
| GFR (mL/min/1.73 m2) | 69±43 | 120±29 | 73±9 | 45±7 | 19±8 | <0.001 |
| (38;63;96) | (96;111;134) | (65;70;81) | (40;44;50) | (12;18;27) | ||
| Creatinine - standardized | 179±113 | 89±21 | 136±49 | 202±72 | 334±115 | <0.001 |
| measurement (µmol/L) | (96;135;231) | (73;84;107) | (108;127;142) | (154;188;237) | 253;319;422) | |
| Homoarginine (µM/L) | 2.57±1.09 | 2.90±1.02 | 2.64±1.06 | 2.52±1.24 | 2.05±0.78 | 0.002 |
GFR denotes glomerular filtration rate measured by iohexol clearance, BMI; body-mass index.
Data are presented as mean ± SD and 25th, 50th (median) and 75th percentiles for skewed variables where appropriate.
P-values are for comparison across all four groups obtained from Kruskal-Wallis test, one-way ANOVA and χ2 test where appropriate.